

SIXTH SUPPLEMENT DATED 31 JANUARY 2022

TO CREDIT SUISSE AG REGISTRATION DOCUMENT DATED 11 JUNE 2021 AND THE PROSPECTUSES LISTED IN SCHEDULE 1

This supplement (the “**Sixth Supplement**”) dated 31 January 2022 supplements (i) for the purposes of Article 10(1) and Article 23(5) of Regulation (EU) 2017/1129, the Credit Suisse AG EU Registration Document which is dated and was approved by the *Commission de Surveillance du Secteur Financier* (the “**CSSF**”) on 11 June 2021 (the “**EU Registration Document**”), and (ii) the Credit Suisse AG Swiss Registration Document which is dated and was approved by the Swiss Reviewing Body on 11 June 2021 (the “**Swiss Registration Document**”), and, together with the EU Registration Document, the “**Registration Document**”) in each case on the terms and for the purposes described therein. This Sixth Supplement constitutes the sixth supplement to the EU Registration Document and the Swiss Registration Document respectively. The terms used but not defined in this Sixth Supplement have the same meaning as such terms used in the Registration Document. For the avoidance of doubt, this Sixth Supplement has been approved by the CSSF only insofar as it relates to the EU Registration Document.

This Sixth Supplement is dated, and has been filed with the Swiss Reviewing Body on, 31 January 2022. For the avoidance of doubt, this Sixth Supplement has been approved by the Swiss Reviewing Body only insofar as it relates to the Swiss Registration Document.

This Sixth Supplement is supplemental to, and should be read in conjunction with, the Registration Document as supplemented by the first supplement to the Registration Document dated 20 July 2021, the second supplement to the Registration Document dated 5 August 2021, the third supplement to the Registration Document dated 29 October 2021, the fourth supplement to the Registration Document dated 12 November 2021 and the fifth supplement to the Registration Document dated 22 December 2021 (collectively, the “**Existing Supplements**”), including the documents incorporated by reference therein. To the extent that there is any inconsistency between (a) any statement in this Sixth Supplement or any statement or information incorporated by reference into the Registration Document by this Sixth Supplement and (b) any other statement or information in or incorporated by reference into the Registration Document as supplemented by the Existing Supplements and/or (c) any other statement or information in or incorporated by reference into the prospectuses listed in Schedule 1 hereto, the statements or information in (a) above will prevail.

This Sixth Supplement has been produced to (i) incorporate by reference specified portions of the Form 6-K Dated 18 January 2022 and the Form 6-K Dated 25 January 2022 (as defined below), (ii) provide information about changes to the Board of Directors of CSG and CS and (iii) update the sections titled “*General Information—5. Significant and Material Change*” (pages 35-37) and “*General Information—6. Names and Addresses of Directors and Executives*” (pages 37 to 56).

Information Incorporated by Reference

The section of the Registration Document titled “About this Registration Document—1. Information Incorporated by Reference” (pages 25 to 31) is hereby amended to include the following information:

Form 6-K Dated 18 January 2022

- xiv. The Form 6-K of CSG and CS filed with the SEC on 18 January 2022 (the “**Form 6-K Dated 18 January 2022**”), which contains a media release titled “Credit Suisse Group appoints Axel P. Lehmann as new Chairman; António Horta-Osório has resigned” as indicated in the cross-reference table below (page 2).

Form 6-K Dated 25 January 2022

- xv. The Form 6-K of CSG and CS filed with the SEC on 25 January 2022 (the “**Form 6-K**”

Dated 25 January 2022”), which contains a media release titled “Credit Suisse Group Trading Update” attached as an exhibit thereto, as indicated in the cross-reference table below.

Form 6-K Dated 18 January 2022			Page(s) of the PDF
	Form 6-K	Entire document except for the sentence “Further information about Credit Suisse can be found at www.credit-suisse.com .”	1 to 6
Form 6-K Dated 25 January 2022			Page(s) of the PDF
	Form 6-K	Entire document except for the sentence “Further information about Credit Suisse can be found at www.credit-suisse.com .”	1 to 7

The information identified in the above table is incorporated by reference into, and forms part of, the Registration Document (and any information not listed in the above table but included in the Form 6-K Dated 18 January 2022 or the Form 6-K Dated 25 January 2022 is not incorporated by reference into the Registration Document and either (a) is covered elsewhere in the Registration Document as supplemented by the Existing Supplements and this Sixth Supplement, or (b) is not relevant for investors).

Only the portions of the Form 6-K Dated 18 January 2022 and the Form 6-K Dated 25 January 2022 specified in the above table have been incorporated by reference into the Registration Document, and not, for the avoidance of doubt, any other parts of such document or the websites referred to in this Sixth Supplement.

The section of the Registration Document titled “About this Registration Document—3. Availability of Documents” (pages 31 to 32) is hereby amended to include the following information:

A copy of the Form 6-K Dated 18 January 2022 and the Form 6-K Dated 25 January 2022 can be obtained, free of charge, on the website of CS (<https://www.credit-suisse.com/>) at:

- <https://www.credit-suisse.com/media/assets/about-us/docs/investor-relations/financial-regulatory-disclosures/regulatory-disclosures/company-registration-documents/form-6-k-dated-18-january-2022.pdf> (the Form 6-K Dated 18 January 2022).
- <https://www.credit-suisse.com/media/assets/about-us/docs/investor-relations/financial-regulatory-disclosures/regulatory-disclosures/company-registration-documents/form-6-k-dated-25-january-2022.pdf> (the Form 6-K Dated 25 January 2022).

Profit Estimate

The Form 6-K Dated 25 January 2022 contains a profit estimate relating to Credit Suisse's expectation of reporting a pre-tax income/(loss) of approximately breakeven for the fourth quarter of 2021, before deduction of the already announced approximately CHF 1.6 billion goodwill impairment for Credit Suisse. This profit estimate has been compiled and prepared on a basis which is both comparable with historical financial information and consistent with CS's accounting policies.

Amendments to the section titled “5. Significant and Material Change” in the Registration Document

The three paragraphs of the section headed “*General Information—5. Significant and Material Change—EU Registration Document*” beginning on page 35 of the Registration Document (as supplemented) are hereby amended and restated as follows:

Apart from (1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in (i) the Registration Document (as supplemented), including in “*Risk Factors—2. Market and Credit Risks—2.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, operations and financial performance*”, (ii) the sections of the Form 20-F Dated 18 March 2021 headed “*II—Operating and financial review—Operating environment*” on pages 60 to 62 (pages 78 to 80 of the PDF file), “*II—Operating and financial review—Credit Suisse—COVID-19 pandemic and related regulatory measures*” on pages 68 to 69 (pages 86 to 87 of the PDF file) and “*III—Treasury, Risk, Balance sheet and Off-balance sheet—Risk management—Key risk developments*” on pages 139 to 141 (pages 157 to 159 of the PDF file), and (iii) the sections of the Form 6-K Dated 4 November 2021 headed “*I—Credit Suisse results—Operating environment*” on pages 4 to 5 (pages 14 to 15 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—COVID-19 pandemic*” on page 16 (page 26 of the PDF file), and “*II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—COVID-19 pandemic*” on page 65 (page 75 of the PDF file) and (2) the consequences of the matters disclosed in (i) the Registration Document (as supplemented), in “*Risk Factors—2. Market and credit risks—2.12 Significant negative consequences of the supply chain finance funds and U.S.-based hedge fund matters*”, (ii) the sections of the Form 6-K Dated 4 November 2021 headed “*I—Credit Suisse results—Credit Suisse—Other information—Mozambique Matter*” on pages 14 to 15 (page 24 to 25 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—Archegos Capital Management*” on page 15 (page 25 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—Supply chain finance funds matter*” on pages 15 to 16 (pages 25 to 26 of the PDF file) and “*I—Credit Suisse results—Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters*” on page 16 (page 26 of the PDF file), “*II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—Archegos and supply chain finance funds matters*” on page 64 (page 74 of the PDF file) and “*III—Condensed consolidated financial statements – unaudited—Notes to the condensed consolidated financial statements – unaudited—Note 3 Business developments and subsequent events—Business developments—Archegos Capital Management*” on page 90 (page 100 of the PDF file) and “*III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Supply chain finance funds matter*” on page 90 (page 100 of the PDF file) and (iii) the Form 6-K Dated 25 January 2022 and Credit Suisse’s expectation of reporting a pre-tax income/(loss) of approximately breakeven for the fourth quarter of 2021, before deduction of the already announced approximately CHF 1.6 billion goodwill impairment for Credit Suisse, there has been no significant change in the financial performance of CS and its consolidated subsidiaries since 30 September 2021.

Apart from (1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in (i) the Registration Document (as supplemented), including in “*Risk Factors—2. Market and Credit Risks—2.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, operations and financial performance*”, (ii) the sections of the Form 20-F Dated 18 March 2021 headed “*II—Operating and financial review—Operating environment*” on pages 60 to 62 (pages 78 to 80 of the PDF file), “*II—Operating and financial review—Credit Suisse—COVID-19 pandemic and related regulatory measures*” on pages 68 to 69 (pages 86 to 87 of the PDF file) and “*III—Treasury, Risk, Balance sheet and Off-balance sheet—Risk management—Key risk developments*” on pages 139 to 141 (pages 157 to 159 of the PDF file), and (iii) the sections of the Form 6-K Dated 4 November 2021 headed “*I—Credit Suisse results—Operating environment*” on pages 4 to 5 (pages 14 to 15 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—COVID-19 pandemic*” on page 16 (page 26 of the PDF file), and “*II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—COVID-19 pandemic*” on page 65 (page 75 of the PDF file) and (2) the consequences of the matters disclosed in (i) the Registration Document (as supplemented), in “*Risk Factors—2. Market and credit risks—2.12 Significant negative consequences of the supply chain finance funds and U.S.-based hedge*

fund matters”, (ii) the sections of the Form 6-K Dated 4 November 2021 headed “*I—Credit Suisse results—Credit Suisse—Other information—Mozambique Matter*” on pages 14 to 15 (page 24 to 25 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—Archegos Capital Management*” on page 15 (page 25 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—Supply chain finance funds matter*” on pages 15 to 16 (pages 25 to 26 of the PDF file) and “*I—Credit Suisse results—Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters*” on page 16 (page 26 of the PDF file), “*II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—Archegos and supply chain finance funds matters*” on page 64 (page 74 of the PDF file) and “*III—Condensed consolidated financial statements – unaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Archegos Capital Management*” on page 90 (page 100 of the PDF file) and “*III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements—unaudited—Note 3 Business developments and subsequent events—Business developments—Supply chain finance funds matter*” on page 90 (page 100 of the PDF file) and (iii) the Form 6-K Dated 25 January 2022 and Credit Suisse’s expectation of reporting a pre-tax income/(loss) of approximately breakeven for the fourth quarter of 2021, before deduction of the already announced approximately CHF 1.6 billion goodwill impairment for Credit Suisse, there has been no significant change in the financial position of CS and its consolidated subsidiaries since 30 September 2021.

Apart from (1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in (i) the Registration Document (as supplemented), including in “*Risk Factors—2. Market and Credit Risks—2.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, operations and financial performance*”, (ii) the sections of the Form 20-F Dated 18 March 2021 headed “*II—Operating and financial review—Operating environment*” on pages 60 to 62 (pages 78 to 80 of the PDF file), “*II—Operating and financial review—Credit Suisse—COVID-19 pandemic and related regulatory measures*” on pages 68 to 69 (pages 86 to 87 of the PDF file) and “*III—Treasury, Risk, Balance sheet and Off-balance sheet—Risk management—Key risk developments*” on pages 139 to 141 (pages 157 to 159 of the PDF file), and (iii) the sections of the Form 6-K Dated 4 November 2021 headed “*I—Credit Suisse results—Operating environment*” on pages 4 to 5 (pages 14 to 15 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—COVID-19 pandemic*” on page 16 (page 26 of the PDF file), and “*II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—COVID-19 pandemic*” on page 65 (page 75 of the PDF file) and (2) the consequences of the matters disclosed in (i) the Registration Document, in “*Risk Factors—2. Market and credit risks—2.12 Significant negative consequences of the supply chain finance funds and U.S.-based hedge fund matters*”, and (ii) the sections of the Form 6-K Dated 4 November 2021 headed “*I—Credit Suisse results—Credit Suisse—Other information—Mozambique Matter*” on pages 14 to 15 (page 24 to 25 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—Archegos Capital Management*” on page 15 (page 25 of the PDF file), “*I—Credit Suisse results—Credit Suisse—Other information—Supply chain finance funds matter*” on pages 15 to 16 (pages 25 to 36 of the PDF file) and “*I—Credit Suisse results—Credit Suisse—Other information—Significant negative consequences of the supply chain finance funds and Archegos matters*” on page 16 (page 26 of the PDF file), “*II—Treasury, risk, balance sheet and off-balance sheet—Risk Management—Key risk developments—Archegos and supply chain finance funds matters*” on page 64 (page 74 of the PDF file) and “*III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements – unaudited—Note 3 Business developments and subsequent events—Business developments—Archegos Capital Management*” on page 90 (page 100 of the PDF file) and “*III—Condensed consolidated financial statements—unaudited—Notes to the condensed consolidated financial statements – unaudited—Note 3 Business developments and subsequent events—Business developments—Supply chain finance funds matter*” on page 90 (page 100 of the PDF file), there has been no material adverse change in the prospects of CS and its consolidated subsidiaries since 31 December 2020.

The paragraph in the section headed “*General Information—5. Significant and Material Change—Swiss Registration Document*” beginning on page 37 of the Registration Document is hereby amended and restated as follows:

Except as otherwise disclosed in the Registration Document (as supplemented) (including the documents incorporated therein by reference), no material changes have occurred in CS's assets and liabilities, financial position or profits and losses since 30 September 2021.

Amendments to the section titled “6. Names and Addresses of Directors and Executives” in the Registration Document

The section titled “*General Information—6. Names and Addresses of Directors and Executives*” beginning on page 37 of the Registration Document (as supplemented) is hereby amended to include the following information:

Changes to Board of Directors

On 17 January 2022, CSG and CS announced the appointment of Axel Lehmann as the new Chairman of the Board of Directors of CSG and CS effective immediately. He succeeds António Horta-Osório, who resigned from the Board of Directors of CSG and CS effective on the same date. Following his appointment by the Board of Directors of CSG and CS, Axel Lehmann has taken office as Chairman. The Board of Directors of CSG and CS will also propose him for election as Chairman at their respective upcoming Annual General Meetings on 29 April 2022.

Effective 17 January 2022, the composition of the Board of Directors of CS* is as follows:

<u>Name</u>	<u>Function</u>
Axel Lehmann	Chairman, Chairman of the Risk Committee
Iris Bohnet	
Clare Brady	
Juan Colombas	
Christian Gellerstad	Chair Conduct and Financial Crime Control Committee
Michael Klein	
Shan Li	
Seraina Macia	
Blythe Masters	
Richard Meddings	Chair Audit Committee
Kai S. Nargolwala	Chair Compensation Committee
Ana Paula Pessoa	
Severin Schwan	Vice-Chair and Lead Independent Director

*The composition of the Board of Directors of CS is the same as the composition of the Board of Directors of CSG.

There are no conflicts of interest between the private interests or other duties of the members of the Board of Directors listed above and their respective duties to CS.

General

This Sixth Supplement and the documents incorporated by reference into the Registration Document by this Sixth Supplement have been filed with the CSSF and the Swiss Reviewing Body, and copies of the Registration Document, the Existing Supplements and this Sixth Supplement and the documents incorporated by reference into the Registration Document (as supplemented by the Existing Supplements and this Sixth Supplement) will be available, free of charge, (i) in electronic form on the website of the Luxembourg Stock Exchange at www.bourse.lu, and on CS's website at <https://www.credit-suisse.com/about-us/en/investor-relations/financial-regulatory-disclosures/regulatory-disclosures/company-registration-documents.html>, and (ii) in printed form during normal business hours from CS at its registered head office at Paradeplatz 8, 8001, Zurich, Switzerland.

Except for the copies of the documents incorporated by reference into the Registration Document as supplemented by the Existing Supplements and this Sixth Supplement that are available on the Luxembourg Stock Exchange website (www.bourse.lu) or CS's website, no

information contained on the websites to which links have been provided is incorporated by reference in the Registration Document.

Save as disclosed in the Existing Supplements and this Sixth Supplement, no other significant new factor, material mistake or inaccuracy relating to information included in the Registration Document has arisen or been noted, as the case may be, since the publication of the Registration Document.

In accordance with Article 23(2a) of Regulation (EU) 2017/1129, investors (excluding investors in Switzerland) who have already agreed to purchase or subscribe for securities pursuant to the prospectuses listed in Schedule 1 hereto before this Sixth Supplement is published have the right, exercisable within three working days after the publication of this Sixth Supplement, to withdraw their acceptances, provided that the significant new factor, material mistake or material inaccuracy referred to in Article 23 paragraph 1 of Regulation (EU) 2017/1129 arose or was noted before the closing of the offer period or the delivery of the securities, whichever occurs first. In connection therewith, investors should contact (i) in the case of prospectuses listed in section 1, CS at its head office at Paradeplatz 8, 8001 Zurich, Switzerland; and (ii) in the case of prospectuses listed in sections 2 and 3, the Distributor (as defined in the relevant prospectus) of such securities. The final date of the right of withdrawal will be 3 February 2022.

Responsibility Statement

EU Registration Document

CS takes responsibility for the Registration Document, as supplemented by the Existing Supplements and this Sixth Supplement. Having taken all reasonable care to ensure that such is the case, the information contained in the Registration Document, as supplemented by the Existing Supplements and this Sixth Supplement, is, to the best knowledge of CS, in accordance with the facts and contains no omission likely to affect its import.

Swiss Registration Document

CS accepts responsibility for the Registration Document, as supplemented by the Existing Supplements and this Sixth Supplement, and declares that the information contained in the Registration Document, as supplemented by the Existing Supplements and this Sixth Supplement is, to the best of its knowledge, correct and no material facts or circumstances have been omitted therefrom.

This Sixth Supplement is not for use in, and may not be delivered to or inside, the United States save where it is incorporated into or referred to in securities offering documentation issued by CS which may be delivered to or inside, the United States.

SCHEDULE 1 – LIST OF PROSPECTUSES TO WHICH THIS SUPPLEMENT RELATES

Section 1

1. Securities Note for the issuance of Yield Enhancement Products of Credit Suisse AG dated 18 June 2021 constituting a base prospectus together with the Registration Document.
2. Securities Note for the issuance of Participation Products of Credit Suisse AG dated 18 June 2021 constituting a base prospectus together with the Registration Document.
3. Securities Note for the issuance by Credit Suisse AG of Complex Products with a Minimum Redemption Amount dated 18 June 2021 constituting a base prospectus together with the Registration Document.
4. Securities Note for the issuance of Mini-Futures of Credit Suisse AG dated 24 June 2021 constituting a base prospectus together with the Registration Document.
5. Securities Note for the issuance of Warrants of Credit Suisse AG dated 24 June 2021 constituting a base prospectus together with the Registration Document.
6. Securities Note for the issuance of Fixed Income Products of Credit Suisse AG dated 23 June 2021 constituting a base prospectus together with the Registration Document.

Section 2

1. Securities Note comprising part of the Trigger Redeemable and Phoenix Securities Base Prospectus dated 9 July 2021.
2. Securities Note comprising part of the Preference Share-Linked Securities (Andrea Preference Share-Linked Securities) Base Prospectus dated 9 July 2021.
3. Securities Note comprising part of the Put and Call Securities Base Prospectus dated 14 July 2021.
4. Securities Note comprising part of the Reverse Convertible and Worst of Reverse Convertible Securities Base Prospectus dated 15 July 2021.
5. Securities Note comprising part of the Bonus and Participation Securities Base Prospectus dated 16 July 2021.
6. Securities Note comprising part of the Credit Suisse AG French Law Programme for the Issuance of Notes dated 10 August 2021.

Section 3

1. Securities Note for the issuance of up to SEK 100,000,000 Flexo NOK Notes linked to the Swedish Small Cap, Listed Real Estate and Global Health Care Equities Funds 12% ER Index, due March 2028, dated 29 December 2021 constituting a base prospectus together with the Registration Document.